Table 1.
Baseline clinical characteristics of glioblastoma patients in original and PSM cohort
| Clinical characteristic | Original cohort | PSM cohort | |
|---|---|---|---|
| Sample size | 291 (100) | 196 (100) | |
| Overall survival | Mean ± SD (day) | 435.6 ± 314.0 | 389.2 ± 282.8 |
| Median (range) | 355 (31–1580) | 304 (31–1580) | |
| Age at diagnosis | Mean ± SD (year) | 53.7 ± 14.2 | 54.2 ± 13.8 |
| Median (range) | 54 (18–85) | 55 (19–85) | |
| Gender | Male | 186 (63.9) | 147 (75.0) |
| Female | 105 (36.1) | 49 (25.0) | |
| Preoperative seizures | Yes | 40 (13.7) | 28 (14.3) |
| No | 251 (86.3) | 168 (85.7) | |
| Karnofsky performance status | ≤ 80 | 183 (62.9) | 123 (62.8) |
| > 80 | 108 (37.1) | 73 (37.2) | |
| Hemisphere | Right | 132 (45.4) | 89 (45.4) |
| Left | 144 (49.5) | 98 (50.0) | |
| Midline or bilateral | 15 (5.1) | 9 (4.6) | |
| Location | Frontal lobe | 98 (33.7) | 60 (30.6) |
| Temporal lobe | 59 (20.3) | 43 (21.9) | |
| Parietal lobe | 26 (8.9) | 18 (9.2) | |
| Occipital lobe | 8 (2.7) | 3 (1.5) | |
| Insular lobe | 12 (4.1) | 10 (5.1) | |
| Other locations | 88 (30.2) | 62 (31.6) | |
| Adjuvant therapy | Yes | 230 (79.0) | 156 (79.6) |
| No or undone | 61 (23.0) | 40 (20.4) | |
| Ki-67 | < 30% | 170 (58.4) | 119 (60.7) |
| ≥ 30% | 121 (41.6) | 77 (39.3) | |
| IDH-1 | Mutant | 42 (14.4) | 27 (13.8) |
| Wildtype | 249 (85.6) | 169 (86.2) | |
| SIRI | < 1.26 | 177 (60.8) | 98 (50.0) |
| ≥ 1.26 | 114 (39.2) | 98 (50.0) | |
| NLR | < 4.86 | 237 (81.4) | – |
| ≥ 4.86 | 54 (18.6) | – | |
| < 4.63 | – | 146 (74.5) | |
| ≥ 4.63 | – | 50 (25.5) | |
Data are presented as n (%)
Abbreviations: IDH-1 isocitrate dehydrogenase-1, SIRI systemic inflammation response index, NLR neutrophil to lymphocyte ratio, PSM propensity score matching